A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

WGCNA: an R package for weighted correlation network analysis

Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252

Harrison's Principles of Internal Medicine.

(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528

Staging of brain pathology related to sporadic Parkinson’s disease

Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382

Harrison's principles of internal medicine

(2008) · Choice Reviews Online · doi:10.5860/choice.46-0330 · Cited by 3,072

Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990

Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders

Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779

Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology

Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease

Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172

Parkinson's disease: a dual‐hit hypothesis

Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021

Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model

Lamontagne‐Proulx, J., Coulombe, K., Dahhani, F., Côté, M., Guyaz, C., Tremblay, C., Marzo, V. D., Flamand, N., Calon, F., & Soulet, D. (2021) · Nutrients · doi:10.3390/nu13124218 · Cited by 14

Overview of Mouse Models of Parkinson's Disease

Bobela, W., Zheng, L., & Schneider, B. L. (2014) · Current Protocols in Mouse Biology · doi:10.1002/9780470942390.mo140092 · Cited by 13

Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson’s Disease

Arab, A., Kučerová, J., Minsterová, A. Š., Dražanová, E., Szabó, N., Starčuk, Z., Rektorová, I., & Khairnar, A. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00068-0 · Cited by 15

Research models to study lewy body dementia

Boschen, S. L., Mukerjee, A. A., Faroqi, A. H., Rabichow, B. E., & Fryer, J. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00837-w · Cited by 16

Integrating artificial intelligence and optogenetics for Parkinson’s disease diagnosis and therapeutics in male mice

Hyeon, B., Shin, J., Lee, J., Kim, W., Kwon, J., Lee, H., Kim, D., Kim, C. Y., Choi, S., Jeong, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63025-w · Cited by 13

Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy

Choi, M.-S., Kim, T.-K., Ahn, J.-H., Lee, J. S., Jung, B. C., An, S., Kim, D., Lee, M. J., Mook‐Jung, I., Lee, S. H., et al. (2022) · Experimental Neurobiology · doi:10.5607/en21039 · Cited by 12

Olfactory deficit and gastrointestinal dysfunction precede motor abnormalities in alpha-Synuclein G51D knock-in mice

Kim, Y. D., McInnes, J., Kim, J., Liang, Y. H. W., Veeraragavan, S., Garza, A. R., Belfort, B. D. W., Arenkiel, B. R., Samaco, R. C., & Zoghbi, H. Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406479121 · Cited by 15

The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases

Klonarakis, M., Vos, M. D., Woo, E. K., Ralph, L. T., Thacker, J. S., & Gil‐Mohapel, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104541 · Cited by 14

Alpha-Synuclein-induced DNA Methylation and Gene Expression in Microglia

McGregor, B. A., Schommer, J., Guo, K., Raihan, M. O., Ghribi, O., Hur, J., & Porter, J. E. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.05.027 · Cited by 13

Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein

Gabrielyan, L., Liang, H., Minalyan, A., Hatami, A., John, V., & Wang, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200983 · Cited by 12

Transgenic Mice Expressing Human α-Synuclein 1-103 Fragment as a Novel Model of Parkinson’s Disease

Tian, Y., He, M., Pan, L., Yuan, X., Xiong, M., Meng, L., Yao, Z., Yu, Z., Ye, K., & Zhang, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.760781 · Cited by 12

A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models

Ghosh, A., Verma, D., Cabrera, G., Ofori, K., Hernandez-Quijada, K., Kim, J., Chung, J. H., Moore, M., Moon, S. H., Seo, J. B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084262 · Cited by 12

Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses

Vasili, E., König, A., Al‐Azzani, M., Bosbach, C., Gatzemeier, L. M., Thom, S., Chegão, A., Miranda, H. V., Steinem, C., Erskine, D., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01159-w · Cited by 14

Alpha-synuclein-induced stress sensitivity renders the Parkinson’s disease brain susceptible to neurodegeneration

Nakos‐Bimpos, M., Karali, K., Antoniou, C., Palermos, D., Fouka, M., Delis, A. D., Tzieras, I., Chrousos, G. P., Koutmani, Y., Stefanis, L., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01797-w · Cited by 11

Construct, Face, and Predictive Validity of Parkinson’s Disease Rodent Models

Guimarães, R. P., de Resende, M. C. S., Tavares, M. M., de Azevedo, C. V. I. B., Ruiz, M. C. M., & Mortari, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168971 · Cited by 18

Alpha synuclein overexpression can drive microbiome dysbiosis in mice

Sampson, T. R., Wallen, Z. D., Won, W.-J., Standaert, D. G., Payami, H., & Harms, A. S. (2025) · Scientific Reports · doi:10.1038/s41598-024-82139-7 · Cited by 11

Role of rodent models in advancing precision medicine for Parkinson's disease

Simons, E., & Fleming, S. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00002-3 · Cited by 10

Modeling Parkinson’s disease in LRRK2 rodents

Domenicale, C., Magnabosco, S., & Morari, M. (2023) · Neuronal Signaling · doi:10.1042/ns20220040 · Cited by 14

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology

Sehlin, D., Roshanbin, S., Zachrisson, O., Ingelsson, M., & Syvänen, S. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00510 · Cited by 11

Alterations in non-REM sleep and EEG spectra precede REM-sleep deficits in a model of synucleinopathy

Käufer, C., Stanojlović, M., Schidlitzki, A., Bonsberger, J., Storch, A., & Richter, F. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241310723 · Cited by 10

Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus

Bender, H., Fietz, S. A., Richter, F., & Stanojlović, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.691560 · Cited by 10

Aging, Parkinson’s Disease, and Models: What Are the Challenges?

Bellantuono, I., Mortiboys, H., Rocha, E. M., Chamoli, M., Chinta, S. J., Andersen, J. K., Wallis, R., Bézard, E., Goldberg, M., Greenamyre, T., et al. (2023) · doi:10.59368/agingbio.20230010 · Cited by 13

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice

Schreglmann, S. R., Regensburger, M., Rockenstein, E. M., Masliah, E., Xiang, W., Winkler, J., & Winner, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126261 · Cited by 10

Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease

Minnella, A., McCusker, K. P., Amagata, A., Trias, B., Weetall, M. L., Latham, J. C., O'Neill, S., Wyse, R. K. H., Klein, M. B., & Trimmer, J. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309893 · Cited by 11

Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation

Lado, W. E., Ham, A., Li, H., Zhang, H., Chang, A. Y., Sardi, S. P., Alcalay, R. N., Arancio, O., Przedborski, S., & Tang, G. (2024) · Brain · doi:10.1093/brain/awae380 · Cited by 8

Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein

Lashuel, H. A., & Novello, S. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105417 · Cited by 9

Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication

Siddu, A., David, L. S., Lauinger, N. D., Chen, X., Saint‐Pierre, M., Alpaugh, M., Durcan, T. M., & Cicchetti, F. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105042 · Cited by 10

Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors

Volta, M., Lavdas, A. Α., Obergasteiger, J., Überbacher, C., Picard, A., Pramstaller, P. P., Hicks, A. A., & Corti, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.11.012 · Cited by 8

IGF2 ‐Reprogrammed Macrophages Ameliorate the Inflammatory Response and Protect Against the Neuroinflammatory Process in Parkinson's Disease Models

Grünenwald, F., Huerta, T. J., Sepúlveda, D., Jerez, C., Urbina, V., Carrera, B., Díaz‐Espinoza, R., Nova, E., Pacheco, R., Martín‐Montañez, E., et al. (2025) · Aging Cell · doi:10.1111/acel.70020 · Cited by 12

Disrupting α-Synuclein–ClpP interaction restores mitochondrial function and attenuates neuropathology in Parkinson’s disease models

Hu, D., Sun, X., & Qi, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00918-w · Cited by 9

Sports-Related Brain Injury and Neurodegeneration in Athletes

Dhote, V. V., Raja, M. K. M. M., Samundre, P., Sharma, S., Anwikar, S., & Upaganlawar, A. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210910114324 · Cited by 8

Preclinical Evaluation of Novel PET Probes for Dementia

Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 9

Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model

Iba, M., Lee, Y., Horan-Portelance, L., Chang, K., Szabo, M. P., Rissman, R. A., You, S., Masliah, E., & Kim, C. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.016 · Cited by 9

Alpha synuclein processing by MMP-3 – implications for synucleinopathies

Bluhm, A., Schrempel, S., Moceri, S., Stieler, J., Feja, M., Schilling, S., Schulze, A., von Hörsten, S., Hartlage‐Rübsamen, M., Richter, F., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114020 · Cited by 9

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model

Morais, L. H., Stiles, L., Freeman, M., Oguienko, A. D., Hoang, J. D., Ji, J., Jones, J. J., Quan, B., Devine, J., Bois, J. S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01142-5 · Cited by 9

Electroacupuncture Modulates 5-HT4R-Mediated cAMP/PKA Signaling to Improve Intestinal Motility Disorders in a Thy1-αSyn Parkinson’s Mouse Model

Shen, L., Wang, Z., Huang, R.-D., Wu, L., Huang, Y., Qi, Q., Zhong, R., Chen, Y., Li, L., & Wu, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8659462 · Cited by 9

Animal Approaches to Studying Risk Factors for Parkinson’s Disease: A Narrative Review

Silva, R. H., Lopes-Silva, L. B., Cunha, D. G., Becegato, M. S., Ribeiro, A. M., & dos Santos, J. R. D. C. M. (2024) · Brain Sciences · doi:10.3390/brainsci14020156 · Cited by 8

Cognitive dysfunction in animal models of human lewy-body dementia

Haikal, C., Winston, G. M., & Kaplitt, M. G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1369733 · Cited by 7

Alpha-synuclein pathology enhances peripheral and CNS immune responses to bacterial endotoxins

Hartke, A.-S., Schreiber, C. S., Lau, K., Wiesweg, I., Waltl, I., Kalinke, U., Richter, F., & Käufer, C. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106773 · Cited by 8

Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[18F]fluoro-L-m-tyrosine imaging and motor performances analysis

Becker, G., Michel, A., Bahri, M. A., Mairet‐Coello, G., Lemaire, C. F., Deprez, T., Freyssin, A., Jacquin, L., Hustadt, F., Wolf, C. D., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.07.012 · Cited by 7

Brain-wide sensory aberrations in a Parkinson’s Disease mouse model revealed by functional MRIPreprint

Lungu, R., Fernandes, F. F., Outeiro, T. F., & Shemesh, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487227 · Cited by 7

Crucial neuroprotective roles of the metabolite BH4 in dopaminergic neuronsPreprint

Cronin, S. J. F., Yu, W., Hale, A., Licht‐Mayer, S., Crabtree, M. J., Korecka, J. A., Tretiakov, E. O., Sealey‐Cardona, M., Somlyay, M., Onji, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539795 · Cited by 7

Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits

Keomanivong, C., Schamp, J. H., Tabakovic, E. E., Thangavel, R., Aldridge, G. M., Pieper, A. A., & Narayanan, N. S. (2024) · eNeuro · doi:10.1523/eneuro.0170-23.2023 · Cited by 6

Synaptic Vesicle Disruption in Parkinson’s Disease: Dual Roles of α-Synuclein and Emerging Therapeutic Targets

Treviño, M., Guerra‐Crespo, M., Padilla-Godínez, F. J., Ortega‐Robles, E., & Arias-Carrión, Ó. (2025) · Brain Sciences · doi:10.3390/brainsci16010007 · Cited by 7

Faecalibacterium prausnitzii, depleted in the Parkinson’s disease microbiome, improves motor deficits in α-synuclein overexpressing mice

Moiseyenko, A., Antonello, G., Schonhoff, A. M., Boktor, J. C., Long, K., Dirks, B., Oguienko, A. D., Winnett, A. V., Simpson, P., Daeizadeh, D., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01287-x · Cited by 8

A minute fraction of α-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition

Taha, H. B., Kearney, B., & Bitan, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1001382 · Cited by 6

Impaired aldehyde detoxification exacerbates motor deficits in an alpha‐synuclein mouse model of Parkinson's disease

Martinez, P. A., Martínez, V., Rani, S., Murrell, M. D., Javors, M. A., Gelfond, J., Doorn, J. A., Fernández, E., & Strong, R. (2023) · Brain and Behavior · doi:10.1002/brb3.3150 · Cited by 6

Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease

Serra, M., Faustini, G., Brembati, V., Casu, M. A., Pizzi, M., Morelli, M., Pinna, A., & Bellucci, A. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115040 · Cited by 6

Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson’s disease model

Alwani, A., Maziarz, K., Burda, G., Jankowska-Kiełtyka, M., Roman, A., Lyszczarz, G., Er, Ş., Barut, J., Barczyk-Woźnicka, O., Pyza, E., et al. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00530-z · Cited by 6

Advanced Immunolabeling Method for Optical Volumetric Imaging Reveals Dystrophic Neurites of Dopaminergic Neurons in Alzheimer’s Disease Mouse Brain

Baek, S., Jang, J., Jung, H. J., Lee, H., & Choe, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03823-9 · Cited by 7

Phenotypic evaluation of a childhood-onset parkinsonism-dystonia mouse model with inherent postural abnormalities

Giraldo, G., & Janus, C. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.10.018 · Cited by 6

Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains

Grigoletto, J., Schechter, M., & Sharon, R. (2022) · Life · doi:10.3390/life12010063 · Cited by 6

Parkinson’s Disease: Basic Pathomechanisms and a Clinical Overview

Noyce, A. J., & Bandopadhyay, R. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_3 · Cited by 7

Drug discovery and development for Parkinson’s disease: are preclinical models good enough?

Reinares-Sebastián, A., Esteban-García, N., Takada, M., & Trigo‐Damas, I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1692592 · Cited by 5

Immunotherapy with an antibody against CD1d modulates neuroinflammation in an α-synuclein transgenic model of Lewy body like disease

Iba, M., Kwon, S., Kim, C., Szabo, M. P., Horan-Portelance, L., Lopez-Ocasio, M. D., Dagur, P. K., Overk, C., Rissman, R. A., & Masliah, E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03087-7 · Cited by 7

Gene-modified animal models of Parkinson's disease

Peng, Y., Jiang, D., Yao, S., Zhang, X., Sugimoto, K., Liu, J. –., Du, M., Lin, L.-Y., Chen, Q., & Hong, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115287 · Cited by 6

Increased blood-brain barrier permeability is associated with dysfunctional α band connectivity in early-stage Parkinson’s disease

Conti, M., Ferrari, V., Pierantozzi, M., Simonetta, C., Carparelli, F., D’Angelo, V., Bagetta, S., Giuliano, F. D., Mercuri, N. B., Schirinzi, T., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03002-1 · Cited by 5

Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson’s Disease as a Multi-System Process

Videlock, E. J., Hatami, A., Zhu, C., Kawaguchi, R., Chen, H., Khan, T., Yehya, A. H. S., Stiles, L., Joshi, S. M., Hoffman, J. M., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-223568 · Cited by 5

A splice‐switching antisense oligonucleotide targeting APP reduces accumulation of α‐synuclein in a mouse model of Parkinson's disease

Ahammad, R. U., Spencer, B. J., Quach, B., Salehi, S. N., & Rissman, R. A. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70117 · Cited by 4

The basolateral amygdala and striatum propagate alpha-synuclein pathology causing increased fear response in a Parkinson’s disease model

Lai, T. T., Xiang, W., Stanojlović, M., Käufer, C., Feja, M., Lau, K., Zunke, F., & Richter, F. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.025 · Cited by 4

Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology

Balta, D., Varghese, A., Huarcaya, S. P., Spiezio, A. D., Marques, A. R. A., Akdaş, E. Y., Tabakacilar, D., Drobny, A., Werner, C. D., Xiang, W., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00886-1 · Cited by 4

Investigating the Pathogenic Interplay of Alpha-Synuclein, Tau, and Amyloid Beta in Lewy Body Dementia: Insights from Viral-Mediated Overexpression in Transgenic Mouse Models

Lim, M. J., Boschen, S. L., Kurti, A., Casey, M. C., Phillips, V. R., Fryer, J. D., Dickson, D. W., Jansen‐West, K. R., Petrucelli, L., Delenclos, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102863 · Cited by 4

Compositional changes in fecal microbiota in a new Parkinson's disease model: C57BL/6-Tg(NSE-haSyn) mice

Kim, J. E., Kwon, K.-C., Jin, Y. J., Seol, A., Song, H. J., Roh, Y. J., Kim, T. R., Park, E. S., Park, G. H., Park, J. W., et al. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00181-4 · Cited by 4

Memantine modulates neuroinflammation and motor coordination in a Parkinson’s disease model

Choi, H., Hwang, S. B., Cho, H. Y., Ahn, S., Yun, H., & Song, J. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150034 · Cited by 3

Depending on intensity, exercise improved or worsened pathology in a model of prodromal Parkinson’s disease

Baldauf, L., Feja, M., Stanojlović, M., Strowig, T., Visscher, C., Schaeffer, E., Berg, D., Hankel, J., & Richter, F. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01200-y · Cited by 3

Effects of acupuncture and moxibustion on PINK1/Parkin signaling pathway in substantia nigra of Thy1-αSyn transgenic mice with Parkinson disease

Xiao, Y., Li, K., Chen, Z., Shen, L., Chen, Y., Lu, J., Xie, J., Li, J., Wang, W., Li, L., et al. (2023) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-023-1401-5 · Cited by 3

Insomnia-related rodent models in drug discovery

Chen, Z.-K., Liu, Y., Zhou, J.-C., Chen, G.-H., Liu, C., Qu, W., & Huang, Z. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01269-w · Cited by 3

Expresión de alfa sinucleína en sangre y su relación con el estreñimiento crónico en población residente en Bogotá, D.C., con problemas de consumo de alcohol

Martínez-Rodríguez, T. Y., & Buitrago, M. R. (2020) · Biomédica · doi:10.7705/biomedica.4771 · Cited by 3

Glycation modulates glutamatergic signalling and exacerbates Parkinson’s disease-like phenotypesPreprint

Chegão, A., Guarda, M., Alexandre, B. M., Shvachiy, L., Temido‐Ferreira, M., Marques-Morgado, I., Gomes, B. F., Matthiesen, R., Lopes, L. V., Florindo, P. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.24.457507 · Cited by 3

Neural and vascular contributions to sensory impairments in a human alpha-synuclein transgenic mouse model of Parkinson’s disease

Lungu, R., Fernandes, F. F., Monteiro, S. P., Outeiro, T. F., & Shemesh, N. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251338952 · Cited by 2

Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study

Strempfl, K., Zattoni, M., Mrowetz, H., Unger, M. S., Schörghofer, N., Altendorfer, B., Neddens, J., Flunkert, S., Hutter‐Paier, B., He, Y., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00690 · Cited by 2

The cross-linking activity of transglutaminase 2 drives α-Synuclein pathology in synucleinopathy models

Hassanzadeh, K., Liu, J., Zhang, J., Tabari, M. A., Maddila, S. C., & Mouradian, M. M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2517886123 · Cited by 2

Neuronal vulnerability in Parkinson’s disease: insights from murine α-synuclein pathology models

Asadpoordezaki, Z., & Prehn, J. H. M. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.04.007 · Cited by 2

Parkinson’s Disease: An Overview of the Non-Motor Symptomatology

van Wamelen, D. J., Leta, V., & Chaudhuri, К. R. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009039291.002 · Cited by 2

Cysteamine HCl Administration Impedes Motor and Olfactory Functions, Accompanied by a Reduced Number of Dopaminergic Neurons, in Experimental Mice: A Preclinical Mimetic Relevant to Parkinson’s Disease

Selvaraj, D. B., Panneerselvam, A., Andrews, J. F. V., & Kandasamy, M. (2024) · Brain Sciences · doi:10.3390/brainsci14070632 · Cited by 2

The gut microbiome in animal models of Parkinson’s disease

Morais, L. H., Fonseca, M. D. C., & Sampson, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13550-7.00010-0 · Cited by 2

Gut microbiota as a potential mechanism besides ketone bodies in Ameliorating Parkinson’s disease symptoms with the ketogenic diet

Luo, J., Luo, J., Zeng, L.-Y., & Chi, C.-L. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111609 · Cited by 2

Immunity in Parkinson's disease – The role of innate responses

Iyengar, A. S., Dunkley, P. R., & Dickson, P. W. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578716 · Cited by 4

Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies

Dahlén, A. D., Roshanbin, S., Bucher, N. M., Sehlin, D., & Syvänen, S. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115475 · Cited by 2

Alpha-synuclein and neuroinflammation in Parkinson's disease

Varanita, T., & Bubacco, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00027-8 · Cited by 2

Olfactory Dysfunction in Parkinson’s Disease and Related Disorders

Doty, R. L., & Hawkes, C. H. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009039291.011 · Cited by 2

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Elgueta, D., Chovar, O., Ugalde, V., Sánchez-Guajardo, V., Catenaccio, A., Court, F. A., & Pacheco, R. (2022) · Journal of Visualized Experiments · doi:10.3791/63313 · Cited by 2

Characterization of FBXO7 (PARK15) knockout mice modeling Parkinsonian-Pyramidal Syndrome

Vingill, S. (2017) · doi:10.53846/goediss-6254 · Cited by 1

Impact of alpha-synuclein pathology on adult neurogenesis: evidence for multilayered mechanisms

Stanojlović, M., Bonsberger, J., & Richter, F. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.330601 · Cited by 1

Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic α-synuclein mouse models of neurodegenerative disease

Vlcek, B., Dumas, S., Ekmark‐Lewén, S., Rubino, E., Ingelsson, M., & Wallén‐Mackenzie, Å. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00053 · Cited by 1

Redirecting microglia phenotype via inhibition of NFAT1 ameliorates deficits in mouse model of synucleinopathies

Iba, M., Lee, Y., Kwon, S., Horan-Portelance, L., Chang, K., Kim, M., Landeck, N., Rissman, R. A., Lee, S. J., You, S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01564-4 · Cited by 3

Comparative Analysis of T-Cell Signatures and Astroglial Reactivity in Parkinson’s Pathology Across Animal Models with Distinct Regenerative Capacities

Intonti, S., Enzmann, V., Perna, A., Spagnolo, F., Curcio, C., & Conedera, F. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020965 · Cited by 1

Pharmacological inhibition of O-GlcNAcase reduces pS129-α-synuclein positive aggregates in the substantia nigra of mThy1-hSNCA mice

Yue, J., Jones, B., Tran, K. H., Deen, M. C., Holicek, V., Cheng, W. H., Michalik, M. J., Power, S. C., Wellington, C. L., Watson, N. V., et al. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x251410291 · Cited by 1

Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models

Maddila, S. C., Hassanzadeh, K., Liu, J., Zhang, J., Ullah, F., Nichols, R. E., & Mouradian, M. M. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03045-7 · Cited by 1

Altered light-dark phase-dependent behavioral responses and suprachiasmatic nucleus pathology in an α-synuclein rat model of Parkinson’s disease

Weber, H., Statz, M., Casadei, N., Rieß, O., Richter, F., Hermann, W., Storch, A., & Fauser, M. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01436-2 · Cited by 1

Protein-First, but Not Protein-Only: Rethinking Neurodegenerative Diseases Through Transgenic Mouse Models

Zeng, C. (2026) · Neurology International · doi:10.3390/neurolint18070139 · Cited by 1

Parkinson’s disease

Magen, I., & Chesselet, M. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.031 · Cited by 2

Neurodegenerative disorders

Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Elgueta, D., Chovar, O., Ugalde, V., Sánchez-Guajardo, V., Catenaccio, A., Court, F. A., & Pacheco, R. (2022) · Journal of Visualized Experiments · doi:10.3791/63313-v · Cited by 1

Deciphering motor dysfunction and microglial activation in mThy1-α-synuclein mice: a comprehensive study of behavioral, gene expression, and methylation changes

McGregor, B. A., Raihan, M. O., Brishti, A., Hur, J., & Porter, J. E. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1544971 · Cited by 1

Genetic Models of Parkinson’s Disease

Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1

Longevity factor klotho and resistance to cognitive deficits in a transgenic mouse model and in individuals with Parkinson’s diseasePreprint

Moreno, A. J., Luthra, N., Bonham, L. W., Lin, J. Y., Broestl, L., Bétourné, A., Sehgal, R., Wang, D., Lesné, S., Ostrem, J. L., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-89525/v1 · Cited by 1

Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease

Prediger, R. D., MATHEUS, F. C., de Oliveira, P. A., Rial, D., Moretti, M., Souza, A. C. G., Aguiar, A. S., & Cunha, R. A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_10

The Non-motor Parkinson’s Disease

Sauerbier, A., Klingelhoefer, L., Qamar, M. A., Carr, H. J., & Chaudhuri, К. R. (2017) · Springer eBooks · doi:10.1007/978-3-7091-1628-9_12

The interplay between α-synuclein and Rab GTPases: Insights into the molecular basis of synucleinopathies

Eisbach, S. E. (2015) · doi:10.53846/goediss-4996

A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice

Richter, F., Stanojlović, M., Käufer, C., Gericke, B., & Feja, M. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01338-0 · Cited by 52

Strengths and limitations of genetic mouse models of Parkinson's disease

Chesselet, M., Fleming, S. M., Mortazavi, F., & Meurers, B. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.004 · Cited by 83

Genetically engineered mouse models of Parkinson's disease

Crabtree, D., & Zhang, J. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.019 · Cited by 73

Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease

Magen, I., Fleming, S. M., Zhu, C., Garcia, E. C., Cardiff, K. M., Dinh, D., Rosa, K. D. L., Sánchez, M. Á., Torres, E. R. S., Masliah, E., et al. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08012.x · Cited by 108

Mouse model for Parkinson's disease (PD)

(2012) · Science-Business eXchange · doi:10.1038/scibx.2012.1243